Stefan Mennel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefan Mennel has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Carsten H. Meyer
Smartlook Augenärzte, Aarau, Schweiz
18 shared publicationsSilvia Peter
Ophthalmology Department; State Hospital Feldkirch; Feldkirch Austria
12 shared publicationsC. H. Meyer
7 shared publicationsJörg C. Schmidt
Department of Ophthalmology, Philipps University, Marburg, Germany
6 shared publicationsJosep Callizo
Department of Ophthalmology, Philipps-University Marburg, Marburg, Germany
4 shared publicationsJ. C. Schmidt
3 shared publications
Latest Publications
- 26 November 2019
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 237 (01) , 90-94
Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen: „Eine Lanze für die Parazentese brechen“
Die Parazentese ist ein über Jahrzehnte lang vertrautes Mittel, um einen erhöhten intraokularen Druck (IOD) unmittelbar, kostenarm und nahezu komplikationslos zu eliminieren. Mit der Zulassung von VEGF-Inhibitoren für die Behandlung der altersbedingten Makuladegeneration (AMD) im Jahr 2007 [1] und dem rapiden Anstieg an intravitrealen Injektionen hat die Bedeutung der Parazentese erneute Aufmerksamkeit erlangt. Fakt ist, dass es mit jeder Volumeneingabe in den Glaskörperraum unweigerlich zu einem IOD-Anstieg kommt, der im individuellen Einzelfall beträchtlich sein und zu akuten Sehbeschwerden und Schmerzen führen kann. Eine Parazentese ist in solchen Fällen zwingend erforderlich, um bleibende Schäden zu vermeiden.
- 26 November 2019
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 237 (01) , 90-94
Sicherheit, Effektivität und protektive Wirkung einer Parazentese bei intravitrealen Injektionen: „Eine Lanze für die Parazentese brechen“
Die Parazentese ist ein über Jahrzehnte lang vertrautes Mittel, um einen erhöhten intraokularen Druck (IOD) unmittelbar, kostenarm und nahezu komplikationslos zu eliminieren. Mit der Zulassung von VEGF-Inhibitoren für die Behandlung der altersbedingten Makuladegeneration (AMD) im Jahr 2007 [1] und dem rapiden Anstieg an intravitrealen Injektionen hat die Bedeutung der Parazentese erneute Aufmerksamkeit erlangt. Fakt ist, dass es mit jeder Volumeneingabe in den Glaskörperraum unweigerlich zu einem IOD-Anstieg kommt, der im individuellen Einzelfall beträchtlich sein und zu akuten Sehbeschwerden und Schmerzen führen kann. Eine Parazentese ist in solchen Fällen zwingend erforderlich, um bleibende Schäden zu vermeiden.
- Open Access
- 5 September 2017
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 32 (1) , 3-11
State of the art und Zukunft der Vitrektomie – Techniken und Instrumente
Zusammenfassung: Hintergrund: Durch die Einführung der Pars plana Vitrektomie ist eine Vielzahl von vitreoretinalen Erkrankungen behandelbar geworden. Kontinuierliche Verbesserungen der Geräte, Instrumente und zusätzliche Hilfsmittel sowie neue Techniken kennzeichnen den enormen Fortschritt der vitreoretinalen Chirurgie. Methoden: In einer Literaturübersicht werden die Operationstechniken verschiedenster vitreoretinaler Eingriffe analysiert. Sofern aufgrund aktueller Entwicklungen verschiedene Optionen in der Operationstechnik bestehen, werden Experten auf dem Gebiet der vitreoretinalen Chirurgie über ihre Erfahrung und ihre Empfehlung befragt. Ergebnisse: Die 20 Gauge Pars plana Vitrektomie wurde größtenteils durch die Verwendung von Trokaren (23, 25 und 27 Gauge) mit entsprechenden Instrumenten mit kleinerem Durchmesser abgelöst. Die Pars plana Vitrektomie ist nahtlos möglich, trotzdem kann es notwendig sein, eine zusätzliche Sicherung der Wunde mit einer Naht durchzuführen, um Leckage und Hypotonie zu vermeiden. Die Visualisierung des Glaskörpers erfolgt zunehmend mit Triamcinolon, epiretinale Gliosen und die Membrana limitans interna werden routinemäßig mit Vitalfarbstoffen dargestellt. Bei der Operationstechnik beim Makulaforamen und bei der Ablatio retinae zeigen sich sowohl bei aktuellen Publikationen als auch unter den Experten Variationen. Schlussfolgerungen: Die Pars plana Vitrektomie hat sich aufgrund der Weiterentwicklung speziell im Bereich der Trokar Systeme, Vitrektome, der Weitwinkel-Beobachtungssysteme sowie dank neuer Techniken zu einer essentiellen OP-Methode für ein weites Indikationsspektrum entwickelt. Dies ist die Basis der Behandlung verschiedenster vitreoretinaler Erkrankungen mit immer weniger Operationstrauma, weniger intraoperativen und postoperativen Komplikationen und gutem Therapieerfolg. Unterschiedliche Operationsvarianten, neue Techniken und die Weiterentwicklung der Geräte und Instrumente sind die Basis für einen auch zukünftigen Fortschritt der Pars plana Vitrektomie.
- 5 September 2017
- Published by Springer Nature in Spektrum der Augenheilkunde
- Vol. 32 (1) , 3-11
Open AccessState of the art und Zukunft der Vitrektomie – Techniken und Instrumente
Zusammenfassung: Hintergrund: Durch die Einführung der Pars plana Vitrektomie ist eine Vielzahl von vitreoretinalen Erkrankungen behandelbar geworden. Kontinuierliche Verbesserungen der Geräte, Instrumente und zusätzliche Hilfsmittel sowie neue Techniken kennzeichnen den enormen Fortschritt der vitreoretinalen Chirurgie. Methoden: In einer Literaturübersicht werden die Operationstechniken verschiedenster vitreoretinaler Eingriffe analysiert. Sofern aufgrund aktueller Entwicklungen verschiedene Optionen in der Operationstechnik bestehen, werden Experten auf dem Gebiet der vitreoretinalen Chirurgie über ihre Erfahrung und ihre Empfehlung befragt. Ergebnisse: Die 20 Gauge Pars plana Vitrektomie wurde größtenteils durch die Verwendung von Trokaren (23, 25 und 27 Gauge) mit entsprechenden Instrumenten mit kleinerem Durchmesser abgelöst. Die Pars plana Vitrektomie ist nahtlos möglich, trotzdem kann es notwendig sein, eine zusätzliche Sicherung der Wunde mit einer Naht durchzuführen, um Leckage und Hypotonie zu vermeiden. Die Visualisierung des Glaskörpers erfolgt zunehmend mit Triamcinolon, epiretinale Gliosen und die Membrana limitans interna werden routinemäßig mit Vitalfarbstoffen dargestellt. Bei der Operationstechnik beim Makulaforamen und bei der Ablatio retinae zeigen sich sowohl bei aktuellen Publikationen als auch unter den Experten Variationen. Schlussfolgerungen: Die Pars plana Vitrektomie hat sich aufgrund der Weiterentwicklung speziell im Bereich der Trokar Systeme, Vitrektome, der Weitwinkel-Beobachtungssysteme sowie dank neuer Techniken zu einer essentiellen OP-Methode für ein weites Indikationsspektrum entwickelt. Dies ist die Basis der Behandlung verschiedenster vitreoretinaler Erkrankungen mit immer weniger Operationstrauma, weniger intraoperativen und postoperativen Komplikationen und gutem Therapieerfolg. Unterschiedliche Operationsvarianten, neue Techniken und die Weiterentwicklung der Geräte und Instrumente sind die Basis für einen auch zukünftigen Fortschritt der Pars plana Vitrektomie.
- 18 June 2014
- Published by Wiley in Acta Ophthalmologica
- Vol. 93 (2)
Cat-scratch-disease-associated macular oedema treated with intravitreal ranibizumab
- 18 June 2014
- Published by Wiley in Acta Ophthalmologica
- Vol. 93 (2)
Cat-scratch-disease-associated macular oedema treated with intravitreal ranibizumab
- 1 January 2014
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 25 (1) , 94-96
Thrombin activity in normal vitreous liquid
An intact blood–retina barrier (BRB) ensures the homeostatic regulation of the retinal environment by preventing proteins and enzymes to pass from the blood stream into the retinal tissue as well as the vitreous cavity (’nonleaky eyes’). Nevertheless, thrombin is needed within the eye to avoid bleeding events. It might, furthermore, play an essential role in preventing BRB breakdown (’leaky eyes’). Until today, the intraocular thrombin activity as well as the source of the latter has not been investigated. The present work was conducted to evaluate whether intravitreal thrombin activity is present in eyes without BRB breakdown. Therefore, 16 vitreal taps were harvested at the beginning of a standard 23-gauge three-port pars plana vitrectomy. These 200 μl undiluted vitreous samples were instantly stabilized by 1 + 1 mixture with 5% human albumin, followed by 1 + 1 mixture of such an aliquot with 2.5 mol/l arginine, pH 8.6, and frozen at −20°C. After thawing at 23°C, thrombin activity was analyzed chromogenically in the presence of arginine protection against unspecific cleavage of the chromogenic substrate. Intravitreal thrombin was detected in all 16 analyzed samples and thrombin activity exhibited to be 1.5 ± 1.0 mIU/ml (mean value ± SD; range: 0.2–3.25 mIU/ml). Thus, our investigation is the first successful quantification of the physiologic intraocular activity of thrombin. Further studies will evaluate intravitreal thrombin activities in eyes with BRB breakdown and compare those results with the physiologic activities demonstrated herein. Standardized intraocular thrombin activity might be a new diagnostic parameter in ophthalmology.
- 1 January 2014
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 25 (1) , 94-96
Thrombin activity in normal vitreous liquid
An intact blood–retina barrier (BRB) ensures the homeostatic regulation of the retinal environment by preventing proteins and enzymes to pass from the blood stream into the retinal tissue as well as the vitreous cavity (’nonleaky eyes’). Nevertheless, thrombin is needed within the eye to avoid bleeding events. It might, furthermore, play an essential role in preventing BRB breakdown (’leaky eyes’). Until today, the intraocular thrombin activity as well as the source of the latter has not been investigated. The present work was conducted to evaluate whether intravitreal thrombin activity is present in eyes without BRB breakdown. Therefore, 16 vitreal taps were harvested at the beginning of a standard 23-gauge three-port pars plana vitrectomy. These 200 μl undiluted vitreous samples were instantly stabilized by 1 + 1 mixture with 5% human albumin, followed by 1 + 1 mixture of such an aliquot with 2.5 mol/l arginine, pH 8.6, and frozen at −20°C. After thawing at 23°C, thrombin activity was analyzed chromogenically in the presence of arginine protection against unspecific cleavage of the chromogenic substrate. Intravitreal thrombin was detected in all 16 analyzed samples and thrombin activity exhibited to be 1.5 ± 1.0 mIU/ml (mean value ± SD; range: 0.2–3.25 mIU/ml). Thus, our investigation is the first successful quantification of the physiologic intraocular activity of thrombin. Further studies will evaluate intravitreal thrombin activities in eyes with BRB breakdown and compare those results with the physiologic activities demonstrated herein. Standardized intraocular thrombin activity might be a new diagnostic parameter in ophthalmology.
- Open Access
- 8 June 2011
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (1) , e74
Macular hole and rhegmatogenous retinal detachment
- 8 June 2011
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (1) , e74
Open AccessMacular hole and rhegmatogenous retinal detachment
- 9 September 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (6) , 590-591
Scleral buckling in rhegmatogenous retinal detachment with concomitant full‐thickness macular hole
- 9 September 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (6) , 590-591
Scleral buckling in rhegmatogenous retinal detachment with concomitant full‐thickness macular hole
- 13 July 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (5) , 610-613
Combined intravitreal anti‐vascular endothelial growth factor (Avastin®) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma
: Objective: Retinal capillary haemangioma complications are characterized by progressive exudation with consecutive intraretinal and subretinal leakage. A successful therapy without side‐effects has not been found. We report a case of retinal juxtapapillary capillary haemangioma causing consecutive leakage with macular involvement. The tumour was treated with a combination of anti‐vascular endothelial growth factor (VEGF) and photodynamic therapy (PDT) and was followed for 1 year.Methods: A 44‐year‐old woman with retinal juxtapapillary capillary haemangioma in the right eye experienced a decrease of visual acuity from 20/20 to 20/60 because of a severe leakage from the tumour involving the macula with lipid depositions. Two sessions of PDT (sparing the part of the haemangioma located within the optic disc) and five injections of bevacizumab were applied in a period of 5 months. Visual acuity, visual field testing, retinal thickness measurements, fundus photography and fluorescein angiography were performed to evaluate the treatment effect.Results: One year after the last injection, visual acuity increased to 20/40. All lipid exudates at the posterior pole resolved. Retinal thickness decreased from 490 to 150 μm with the restoration of normal central macular architecture. Leakage in fluorescence angiography reduced significantly, but hyperfluorescence of the tumour was still evident. Visual field testing and angiography did not show any treatment‐related vaso‐occlusive side‐effects.Conclusion: In this single case, the combination of anti‐VEGF and PDT appeared to be an effective strategy for the treatment of retinal juxtapapillary capillary haemangioma without side‐effects. Further studies with a greater number of eyes and adequate follow‐up are necessary to support these first clinical results.
- 13 July 2010
- Published by Wiley in Acta Ophthalmologica
- Vol. 88 (5) , 610-613
Combined intravitreal anti‐vascular endothelial growth factor (Avastin®) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma
: Objective: Retinal capillary haemangioma complications are characterized by progressive exudation with consecutive intraretinal and subretinal leakage. A successful therapy without side‐effects has not been found. We report a case of retinal juxtapapillary capillary haemangioma causing consecutive leakage with macular involvement. The tumour was treated with a combination of anti‐vascular endothelial growth factor (VEGF) and photodynamic therapy (PDT) and was followed for 1 year.Methods: A 44‐year‐old woman with retinal juxtapapillary capillary haemangioma in the right eye experienced a decrease of visual acuity from 20/20 to 20/60 because of a severe leakage from the tumour involving the macula with lipid depositions. Two sessions of PDT (sparing the part of the haemangioma located within the optic disc) and five injections of bevacizumab were applied in a period of 5 months. Visual acuity, visual field testing, retinal thickness measurements, fundus photography and fluorescein angiography were performed to evaluate the treatment effect.Results: One year after the last injection, visual acuity increased to 20/40. All lipid exudates at the posterior pole resolved. Retinal thickness decreased from 490 to 150 μm with the restoration of normal central macular architecture. Leakage in fluorescence angiography reduced significantly, but hyperfluorescence of the tumour was still evident. Visual field testing and angiography did not show any treatment‐related vaso‐occlusive side‐effects.Conclusion: In this single case, the combination of anti‐VEGF and PDT appeared to be an effective strategy for the treatment of retinal juxtapapillary capillary haemangioma without side‐effects. Further studies with a greater number of eyes and adequate follow‐up are necessary to support these first clinical results.
- 8 July 2010
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 228 (05) , 460-464
Der Einfluss des Glaskörpers auf die Pathogenese der altersabhängigen Makuladegeneration
Die altersabhängige Makuladegeneration (AMD) ist die häufigste Ursache für einen massiven Visusabfall mit Zentralskotom im Alter. Die AMD stellt eine multifaktorielle Erkrankung dar, die bis zum Einsatz von anti-VEGF in ihrer Therapiemöglichkeit äußerst limitiert war. Trotz aller Fortschritte ist allerdings in den meisten Fällen keine langfristige Heilung zu erreichen. Der Glaskörper wird aktuell – aufgrund seiner anatomischen Lokalisation an der Makula – als möglicher Co-Faktor in der Pathogenese der AMD diskutiert. Zahlreiche Autoren konnten einen anliegenden Glaskörper deutlich häufiger bei der exsudativen Form der AMD nachweisen. Altersunterschiede, genetische Abweichungen und Umweltfaktoren konnten dabei weitgehend ausgeschlossen werden. Entscheidend ist die Frage, inwieweit eine Beeinflussung des Glaskörpers die Entstehung und den Verlauf der AMD verändern kann. Hierzu liegen nur einzelne Fallberichte und Fallserien vor. Eine multizentrische, prospektive, verblindete, vergleichende, randomisierte klinische Studie zur enzymatischen Vitreolyse untersucht gegenwärtig die Effekte einer Glaskörperabhebung auf die Progression einer exsudativer AMD. Die Ergebnisse sind abzuwarten, um beurteilen zu können, inwieweit die Glaskörperabhebung eine Therapieoption der exsudativen AMD in Zukunft darstellen wird. Age-related macular degeneration (AMD) is the main cause of severe visual decease in elderly people in the industrialised countries. AMD is a multifactorial disease with only limited therapeutic options before anti-VEGF treatment was introduced. In spite of all the progress no long-term healing is possible. Actually, the vitreous is being investigated as a possible co-factor in the pathogenesis of AMD. Numerous authors demonstrated a higher incidence of vitreoretinal adhesion in exudative AMD by considering age, genetic and environmental factors. The essential question is whether the therapeutic release of vitreoretinal adhesion could affect the development and progress of AMD. Up to now only case reports and case series have demonstrated a positive effect on disease progress. An ongoing multicentre, prospective, comparative, randomised, double-blind clinical trial with enzymatic vitreolysis is now evaluting the effect of vitreoretinal release on the progress of AMD. The results are necessary to evaluate whether vitreoretinal release is a therapeutic option for the future.
- 8 July 2010
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 228 (05) , 460-464
Der Einfluss des Glaskörpers auf die Pathogenese der altersabhängigen Makuladegeneration
Die altersabhängige Makuladegeneration (AMD) ist die häufigste Ursache für einen massiven Visusabfall mit Zentralskotom im Alter. Die AMD stellt eine multifaktorielle Erkrankung dar, die bis zum Einsatz von anti-VEGF in ihrer Therapiemöglichkeit äußerst limitiert war. Trotz aller Fortschritte ist allerdings in den meisten Fällen keine langfristige Heilung zu erreichen. Der Glaskörper wird aktuell – aufgrund seiner anatomischen Lokalisation an der Makula – als möglicher Co-Faktor in der Pathogenese der AMD diskutiert. Zahlreiche Autoren konnten einen anliegenden Glaskörper deutlich häufiger bei der exsudativen Form der AMD nachweisen. Altersunterschiede, genetische Abweichungen und Umweltfaktoren konnten dabei weitgehend ausgeschlossen werden. Entscheidend ist die Frage, inwieweit eine Beeinflussung des Glaskörpers die Entstehung und den Verlauf der AMD verändern kann. Hierzu liegen nur einzelne Fallberichte und Fallserien vor. Eine multizentrische, prospektive, verblindete, vergleichende, randomisierte klinische Studie zur enzymatischen Vitreolyse untersucht gegenwärtig die Effekte einer Glaskörperabhebung auf die Progression einer exsudativer AMD. Die Ergebnisse sind abzuwarten, um beurteilen zu können, inwieweit die Glaskörperabhebung eine Therapieoption der exsudativen AMD in Zukunft darstellen wird. Age-related macular degeneration (AMD) is the main cause of severe visual decease in elderly people in the industrialised countries. AMD is a multifactorial disease with only limited therapeutic options before anti-VEGF treatment was introduced. In spite of all the progress no long-term healing is possible. Actually, the vitreous is being investigated as a possible co-factor in the pathogenesis of AMD. Numerous authors demonstrated a higher incidence of vitreoretinal adhesion in exudative AMD by considering age, genetic and environmental factors. The essential question is whether the therapeutic release of vitreoretinal adhesion could affect the development and progress of AMD. Up to now only case reports and case series have demonstrated a positive effect on disease progress. An ongoing multicentre, prospective, comparative, randomised, double-blind clinical trial with enzymatic vitreolysis is now evaluting the effect of vitreoretinal release on the progress of AMD. The results are necessary to evaluate whether vitreoretinal release is a therapeutic option for the future.
- 7 May 2009
- Published by S. Karger AG in Ophthalmologica
- Vol. 223 (5) , 313-319
Radial Optic Neurotomy for Central Retinal Vein Occlusion: Long-Term Retinal Perfusion Outcome
Background/Aims:To analyze the long-term changes in retinal perfusion and functional improvement induced by radial optic neurotomy (RON) in central retinal vein occlusion (CRVO). Methods: Sixty-three eyes of 63 consecutive patients with CRVO were included. Twenty-eight (44.5%) patients underwent RON and 35 (55.5%) were followed as a control group. Time of arteriovenous transit and visual acuity were determined at baseline and after 1-year follow-up. Results:After 1 year, retinal perfusion status improved in 63.1% of operated eyes and 14.3% of controls (p = 0.048). The improvement in arteriovenous retinal transit was statistically significant (p = 0.023) only in the RON group. The visual improvement in the RON group was significantly better (p = 0.043) than in the control group. Moreover, the development of chorioretinal anastomosis was significantly higher (p = 0.036) after RON than in controls and correlated with better functional results. In operated eyes there was a lower incidence of CRVO-related complications. Conclusion:RON improved retinal perfusion and achieved a better functional outcome. The measurement of perfusion changes as presented here may be useful for monitoring CRVO and assessing other treatment modalities.
- 7 May 2009
- Published by S. Karger AG in Ophthalmologica
- Vol. 223 (5) , 313-319
Radial Optic Neurotomy for Central Retinal Vein Occlusion: Long-Term Retinal Perfusion Outcome
Background/Aims:To analyze the long-term changes in retinal perfusion and functional improvement induced by radial optic neurotomy (RON) in central retinal vein occlusion (CRVO). Methods: Sixty-three eyes of 63 consecutive patients with CRVO were included. Twenty-eight (44.5%) patients underwent RON and 35 (55.5%) were followed as a control group. Time of arteriovenous transit and visual acuity were determined at baseline and after 1-year follow-up. Results:After 1 year, retinal perfusion status improved in 63.1% of operated eyes and 14.3% of controls (p = 0.048). The improvement in arteriovenous retinal transit was statistically significant (p = 0.023) only in the RON group. The visual improvement in the RON group was significantly better (p = 0.043) than in the control group. Moreover, the development of chorioretinal anastomosis was significantly higher (p = 0.036) after RON than in controls and correlated with better functional results. In operated eyes there was a lower incidence of CRVO-related complications. Conclusion:RON improved retinal perfusion and achieved a better functional outcome. The measurement of perfusion changes as presented here may be useful for monitoring CRVO and assessing other treatment modalities.
- 22 July 2008
- Published by Wiley in Acta Ophthalmologica
- Vol. 86 (5) , 579-581
Secondary pigmented macular pucker on optical coherence tomography
To describe the clinical features, retinal architecture and tomographic configuration of a pigmented epiretinal membrane on optical coherence tomography (OCT). A 52-year-old man presented during a routine examination with an asymptomatic, darkly pigmented, pre-retinal epiretinal membrane in his right eye. His best corrected visual acuity (BCVA) on Snellen charts was 20/25 in the right eye and 20/20 in the left. The patient complained of no visual symptoms or metamorphopsia. In the fundus periphery there was a small, old, well pigmented retinal hole with pigmentation in its immediate vicinity, without signs of vitreal traction, which required no treatment. The foveal indentation was not apparent on OCT and a well demarcated hyperreflective band defined the pigmented epiretinal membranes (ERMs). Sequential fundus examination over a 2-year period demonstrated no functional or anatomical deterioration attributable to the disease. Pigmented ERM may have different cellular origins depending on the underlying pathology. Patients with pigmented ERM and full VA should be followed by sequential OCT.
- 22 July 2008
- Published by Wiley in Acta Ophthalmologica
- Vol. 86 (5) , 579-581
Secondary pigmented macular pucker on optical coherence tomography
To describe the clinical features, retinal architecture and tomographic configuration of a pigmented epiretinal membrane on optical coherence tomography (OCT). A 52-year-old man presented during a routine examination with an asymptomatic, darkly pigmented, pre-retinal epiretinal membrane in his right eye. His best corrected visual acuity (BCVA) on Snellen charts was 20/25 in the right eye and 20/20 in the left. The patient complained of no visual symptoms or metamorphopsia. In the fundus periphery there was a small, old, well pigmented retinal hole with pigmentation in its immediate vicinity, without signs of vitreal traction, which required no treatment. The foveal indentation was not apparent on OCT and a well demarcated hyperreflective band defined the pigmented epiretinal membranes (ERMs). Sequential fundus examination over a 2-year period demonstrated no functional or anatomical deterioration attributable to the disease. Pigmented ERM may have different cellular origins depending on the underlying pathology. Patients with pigmented ERM and full VA should be followed by sequential OCT.